GALT
Galectin Therapeutics Inc
Halal Rating :
Last Price
$1.23
Last updated:
Market Cap
-
7D Change
10.81%
1 Year Change
-29.71%
Company Overview
Industries
Exchange
Next Earnings Date
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases and cancer. The company's lead compound is belapectin (GR-MD-02), which is being developed primarily for the treatment of non-alcoholic steatohepatitis (NASH) cirrhosis.
The company is currently in research and development phase and does not generate revenue from product sales. Their primary activities involve clinical trials and research to develop treatments for chronic liver and skin diseases.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Galectin Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.